Tdam USA Inc. lessened its position in shares of Eli Lilly And Co (NYSE:LLY) by 8.6% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 11,990 shares of the company’s stock after selling 1,125 shares during the period. Tdam USA Inc.’s holdings in Eli Lilly And Co were worth $1,387,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently modified their holdings of the company. FMR LLC grew its stake in shares of Eli Lilly And Co by 172.9% in the 2nd quarter. FMR LLC now owns 1,188,301 shares of the company’s stock valued at $101,398,000 after purchasing an additional 752,864 shares during the last quarter. Douglass Winthrop Advisors LLC purchased a new position in shares of Eli Lilly And Co in the 3rd quarter valued at approximately $373,000. Capital Investment Advisors LLC lifted its holdings in shares of Eli Lilly And Co by 6.0% in the 3rd quarter. Capital Investment Advisors LLC now owns 35,556 shares of the company’s stock valued at $3,816,000 after buying an additional 2,018 shares during the period. Stock Yards Bank & Trust Co. lifted its holdings in shares of Eli Lilly And Co by 41.5% in the 3rd quarter. Stock Yards Bank & Trust Co. now owns 54,399 shares of the company’s stock valued at $5,837,000 after buying an additional 15,956 shares during the period. Finally, First Hawaiian Bank acquired a new stake in shares of Eli Lilly And Co in the 3rd quarter valued at approximately $912,000. 80.84% of the stock is owned by institutional investors.

Several equities analysts recently issued reports on LLY shares. Zacks Investment Research raised Eli Lilly And Co from a “hold” rating to a “buy” rating and set a $133.00 price objective for the company in a report on Wednesday, December 5th. UBS Group cut their price target on Eli Lilly And Co from $107.53 to $100.00 and set an “average” rating for the company in a report on Friday. Cantor Fitzgerald reissued a “buy” rating and issued a $128.00 price target on shares of Eli Lilly And Co in a report on Wednesday, October 17th. Wolfe Research assumed coverage on Eli Lilly And Co in a report on Tuesday, October 23rd. They issued a “market perform” rating and a $119.00 price target for the company. Finally, Societe Generale set a $106.00 price target on Eli Lilly And Co and gave the stock a “hold” rating in a report on Wednesday, November 7th. Eleven investment analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. The company currently has an average rating of “Buy” and an average price target of $111.41.

In other Eli Lilly And Co news, SVP Alfonso G. Zulueta sold 4,000 shares of the business’s stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $120.00, for a total transaction of $480,000.00. The sale was disclosed in a legal filing with the SEC, which is available at this link. Also, major shareholder Lilly Endowment Inc sold 195,000 shares of the business’s stock in a transaction dated Monday, November 19th. The stock was sold at an average price of $115.31, for a total value of $22,485,450.00. Following the transaction, the insider now owns 118,505,584 shares in the company, valued at approximately $13,664,878,891.04. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 817,843 shares of company stock worth $94,595,335. 0.11% of the stock is currently owned by insiders.

LLY stock traded down $2.38 during trading on Monday, reaching $117.22. 1,743,701 shares of the stock traded hands, compared to its average volume of 5,609,386. Eli Lilly And Co has a 52-week low of $73.69 and a 52-week high of $121.84. The company has a current ratio of 1.91, a quick ratio of 1.53 and a debt-to-equity ratio of 0.83. The company has a market cap of $125.67 billion, a PE ratio of 21.12, a price-to-earnings-growth ratio of 1.91 and a beta of 0.37.

Eli Lilly And Co (NYSE:LLY) last issued its quarterly earnings data on Wednesday, February 6th. The company reported $1.33 EPS for the quarter, missing the Zacks’ consensus estimate of $1.36 by ($0.03). The company had revenue of $6.44 billion for the quarter, compared to analyst estimates of $6.28 billion. Eli Lilly And Co had a return on equity of 42.55% and a net margin of 13.16%. The company’s revenue for the quarter was up 4.5% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.14 EPS. Equities analysts forecast that Eli Lilly And Co will post 5.6 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 8th. Shareholders of record on Friday, February 15th will be paid a dividend of $0.645 per share. This represents a $2.58 dividend on an annualized basis and a dividend yield of 2.20%. The ex-dividend date of this dividend is Thursday, February 14th. This is a boost from Eli Lilly And Co’s previous quarterly dividend of $0.56. Eli Lilly And Co’s payout ratio is currently 40.54%.

ILLEGAL ACTIVITY WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/eli-lilly-and-co-lly-stake-decreased-by-tdam-usa-inc/2813094.html.

Eli Lilly And Co Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates through two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Featured Article: Why Net Income is Important to Investors

Institutional Ownership by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.